neratinib
PUMA-NER-1301
Phase 3 small_molecule completed
Quick answer
neratinib for HER2+ Metastatic Breast Cancer (MBC) is a Phase 3 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PUMA BIOTECHNOLOGY, INC.
- Indication
- HER2+ Metastatic Breast Cancer (MBC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed